Related Experiment Video
Updated: Jun 18, 2026

An Immature Murine Model of Reversible Unilateral Ureteral Obstruction
Published on: April 4, 2025
Rasburicase improves hyperuricemia in infants with acute kidney injury
David J Hobbs1, Julia M Steinke, Jin Y Chung
1Pediatric Nephrology, Dialysis and Transplantation, Helen DeVos Children's Hospital and Michigan State University College of Human Medicine, 221 Michigan Street SE, Suite 406, Grand Rapids, MI 49503, USA.
Insights
Rasburicase effectively treated hyperuricemia in infants with acute kidney injury (AKI). A single dose normalized uric acid levels and improved kidney function without side effects, showing promise for this novel treatment.
Area of Science:
- Nephrology
- Pediatrics
- Biochemistry
Background:
- Elevated uric acid (UA) levels are increasingly linked to renal disease progression.
- Rasburicase, a recombinant urate oxidase, is a proven treatment for hyperuricemia in tumor lysis syndrome.
- Its potential in managing hyperuricemia secondary to acute kidney injury (AKI) in infants requires investigation.
Purpose of the Study:
- To evaluate the safety and efficacy of rasburicase in treating hyperuricemia in infants diagnosed with AKI.
- To assess the impact of rasburicase on serum uric acid levels, renal function, and urinary output in this pediatric population.
Main Methods:
- A retrospective chart review was conducted on infants with hyperuricemia (UA > 8 mg/dl) and AKI (serum creatinine > 1.5 mg/dl).
- Seven infants received a single, intravenous bolus of rasburicase (0.17 ± 0.04 mg/kg).
- Data on serum UA, creatinine levels, and urinary output were collected before and after treatment.
Main Results:
- Within 24 hours, serum UA decreased significantly (13.6 to 0.9 mg/dl, P < 0.05), and creatinine levels improved (3.2 to 2.0 mg/dl, P < 0.05).
- Urinary output increased significantly (2.4 to 5.9 ml/kg/hr, P < 0.05) post-treatment.
- Sustained improvements were observed in the following week without UA rebound, and no treatment-related side effects were reported.
Conclusions:
- A single intravenous dose of rasburicase is a safe and effective novel treatment for hyperuricemia in infants with AKI.
- Rasburicase facilitated normalization of uric acid levels and improved renal function, potentially avoiding the need for renal replacement therapy.
Abstract:
Recent data suggest that elevated levels of uric acid (UA) might contribute to the progression of renal disease. Rasburicase, recombinant urate oxidase, is a highly safe and efficacious hypo-uricosuric agent for treatment of elevated UA levels from tumor lysis. We adopted the use of rasburicase for management of hyperuricemia in infants with acute kidney injury (AKI) and, herein, report our experience. We conducted a retrospective chart review of infants with hyperuricemia (UA > 8 mg/dl) secondary to AKI (serum creatinine > 1.5 mg/dl) treated with rasburicase. Seven infants (mean age 34 +/- 55 days, six male), with a mean weight of 3.2 +/- 1.2 kg, were identified. Rasburicase was administered intravenously as a single, onetime, bolus of 0.17 +/- 0.04 mg/kg body weight. Within 24 h, serum UA had decreased from 13.6 +/- 4.5 mg/dl to 0.9 +/- 0.6 mg/dl (P < 0.05), creatinine had decreased from 3.2 +/- 2.0 mg/dl to 2.0 +/- 1.2 mg/dl (P < 0.05), and urinary output had increased from 2.4 +/- 1.2 ml/kg per hour to 5.9 +/- 1.8 ml/kg per hour (P < 0.05). Continued improvements in UA, creatinine, and urinary output were observed in the week following administration of rasburicase, without rebound of the UA. We observed no treatment-related side effects. All patients demonstrated a normalization of uric acid level without need of renal replacement therapy. In conclusion, a single intravenously administered bolus of rasburicase appears to be a novel treatment for hyperuricemia in infants with AKI.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Urinary Tract Calculi V: Nursing Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Acute Kidney Injury I: Introduction
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
